News Stories

Pavani Chalasani, MD, MPH; Robert Livingston, MD

Pavani Chalasani, MD, MPH, has high hopes for the future of cancer treatment. At the University of Arizona Cancer Center, her mentors are helping her turn those hopes into reality.


¡VIDA! The Seventh Annual Mujer Latina Breast Cancer Conference will be held Oct. 6 at Apollo Community School. Topics will include cancer screening, understanding risk factors, treatment options and survivorship, with presentations delivered in Spanish and English.

The University of Arizona Cancer Center (UACC) is leading the first large nationwide study to determine how diet and physical activity together can improve the quality of life and prevent recurrence for women who are in clinical complete remission from advanced ovarian peritoneal or tubal cancer.

Four teams of UACC researchers received a total of $90,000 from the Basic-Clinical Partnerships Research Grant program to move forward on a variety of translational research pilot projects.

UA Cancer Center researchers continue to seek participants in a study designed to determine if a compound found in broccoli can enhance the effects of the breast cancer drug Tamoxifen.

David S. Alberts, MD

University of Arizona Cancer Center director David S. Alberts, MD, is among this year’s Lifetime Achievement honorees at the 2012 AZBio Awards for Achievement, to be held Oct. 23 at the Phoenix Convention Center.

University of Arizona Cancer Center researchers Mark D. “Marty” Pagel, PhD, and Kimberly McDermott, PhD, were named this year’s recipients of the Better Than Ever Program’s grant awards.

The University of Arizona Cancer Center has completed the initial steps of its search for a new director, identifying five candidates for campus visits and in-depth interviews.

Natalia Ignatenko, PhD

Natalia Ignatenko, PhD, has been awarded $1.6 million by the National Cancer Institute to study the role of Kallikrein 6 in colon cancer.

Alison Stopeck, MD, and Patricia Thompson, PhD, have been awarded $1.7 million by the NIH National Cancer Institute to study NSAID effects on clinical and imaging breast biomarkers.